AbbVie Beats Antitrust Challenge To Humira 'Patent Thicket'
Law360 (June 8, 2020, 7:02 PM EDT) -- Humira buyers have alleged neither an antitrust violation nor an antitrust injury in their novel lawsuit claiming AbbVie built a "patent thicket" around its immunosuppressant drug Humira to block cheaper biosimilars from coming onto the market, an Illinois federal judge ruled Monday.
A judge threw out drug buyers' claims that AbbVie illegally created a "patent thicket" around its $20-billion-per-year immunosuppressant Humira by aggressively using invalid, unenforceable or noninfringed patents. (AP Photo/Nam Y. Huh, File)
The proposed class of Humira purchasers had made groundbreaking accusations that AbbVie repeatedly and aggressively asserted swaths of invalid, unenforceable or noninfringed patents to edge out competition and boost...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!